Featured White Paper
March 2, 2021
COVID Plus: A New Diagnostic Tool to Protect Transplant Patients in the Fight Against COVID-19
By: Dave Lowe
We do not yet fully understand the impact of a COVID-19 infection on the HLA antibody status of transplant recipients. Researchers have long observed that episodes of viral infection can lead to alterations in the HLA antibody profiles of transplant patients. We must consider, therefore, that a COVID-19 infection, as well as any future COVID-19 vaccine, may trigger changes in HLA antibody profiles. This, in turn, may have a profound effect on patients’ eligibility for transplant and risk of rejection after transplant. Additionally, an assay for transplant patients that could both detect neutralizing antibodies and rule out false positives will be critical for fully characterizing the immune response to COVID-19. The LABScreen™ COVID Plus assay can uniquely characterize these changes with greater accuracy by detecting multiple distinct antibodies and fragments, making it not only more specific than current assays but also more adept at reducing false positives caused by seasonal coronaviruses. These powerful features will enable physicians to adapt patient care for better transplant outcomes.
- The impact of an episode of COVID-19 infection and of future vaccine administration on HLA antibody status is unknown.
- Distinguishing a true instance of COVID-19 infection will help to differentiate the impact of other seasonal respiratory infections.
- Identifying multiple distinct antibodies to COVID-19 will be vitally important as some have demonstrated neutralizing capabilities.
The effect of the global coronavirus disease 2019 (COVID-19) pandemic on the field of transplantation has been profound. In excess of 75% of kidney and liver transplant programs have either been suspended or are operating with greatly reduced capacity1. The overwhelming need to protect our immunologically vulnerable transplant patients and the healthcare workers who care for them has been key to guiding these drastic protective efforts.
However, the time has come to reopen the clinics and operating theaters to resume transplant activity. In order to do this safely, the development of new diagnostic tools is required to enable the transplant laboratory to assess the risk of SARS-CoV-2, the underlying disease of COVID-19. Current data shows the mortality rate among transplant recipients who test positive for COVID-19 can be as high as 32%2.
Consider the body of evidence currently available that indicates how active infectious episodes can result in profound changes to the patients’ HLA antibody profile3. While the exact mechanisms that underpin these processes remain controversial, the emerging consensus is that pathogenic viral infections, such as COVID-19, may trigger an anamnestic B-cell response. Such memory responses can result in an increase in both the breadth and strength of the HLA antibody response4.
Additionally, the current mass mobilization of the scientific community for the development of a safe and effective COVID-19 vaccine may pose additional challenges for transplant patients. Data has indicated that vaccine administration also has the potential to induce changes in the HLA antibody repertoire of our transplant patients5,6. By monitoring antibody responses post COVID-19 vaccination, we can detect changes and, if transplant eligibility or existing graft health is impacted, better manage the associated risk factors for these conditions.
In order to fully understand a patient’s risk factor, transplant teams need be able to characterize the immune response to COVID-19 by simultaneously detecting the response to the spike protein, receptor-binding domain, nucleocapsid and other SARS-CoV-2 proteins.
Viral- and vaccination-induced changes to HLA sensitization status can have a profound impact on both transplant waitlist candidates and on those looking to preserve function in their transplanted organ. In response to this unmet patient need, we have developed the LABScreen COVID Plus assay, a comprehensive SARS-CoV-2 specific antibody detection panel that takes advantage of the multiplex capability off ered by the Luminex platform. It can be run in parallel with conventional LABScreen products to give the full picture of a patients’ HLA and COVID antibody status.
By uniquely targeting multiple subunits of the extracellular domain (commonly referred to as the “spike” protein) as well as the internal nucleocapsid protein, the LABScreen COVID Plus assay provides a reliable detection system (Fig. 1). The kinetics of the antibody response to SARS-CoV-2 are now reasonably well described with antibodies being routinely detected within 7-14 days after the onset of symptoms7. The added specificity of the LABScreen COVID Plus assay takes on greater importance since recent studies have indicated that individuals who develop antibodies to the viral nucleocapsid suff er increased mortality compared to those whose humoral response is limited to the recognition of spike protein8. In contrast, studies have indicated that the antibodies to the spike subunits RBD and S1 may have a neutralizing eff ect9 (Fig. 2). The benefit of the antibody to Spike S2 is unknown, although detection of the Spike S2 antibody would indicate exposure to COVID-19. Clinical relevance of antibodies to Spike S2 may be established with future studies.
Furthermore, the panel for LABScreen COVID Plus includes specific targets for the common cold coronavirus families and markers for Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), thereby reducing the possibility that cross-reactive viral response may give rise to false positive COVID-19 tests.
The LABScreen COVID Plus assay will facilitate the detection and monitoring of the post-COVID antibody response, the assessment of antibody responses to vaccination (both COVID- and HLA-specific), and the exploration of changes to HLA antibody profiles. When combined with any of the currently available LABScreen HLA panels, the COVID Plus solution provides a tailored suite of antibody monitoring diagnostic tools specific for transplant patients.
Comprehensive SARS-CoV-2 Screening Capability
The SARS-CoV-2 genome encodes four major structural proteins; spike, envelope, membrane, and nucleocapsid. Most commercially available tests target either the spike subunits or nucleocapsid. The LABScreen ™ COVID Plus assay targets these proteins and identifies antibody responses to community coronaviruses, original SARS and MERS viruses, some of which have been shown to cross-react with SARS-CoV-2 in other tests.
Features & Benefits of LABScreen COVID Plus
- Batch with available LABScreen HLA assays to detect COVID-19 and HLA antibodies in a single run
- Comprehensive SARS-CoV-2 specific multiplex antibody detection panel
- Minimize cross reactivity with seasonal coronaviruses, MERS, and SARS infection
- Optimized assay workflow compatible with both LABScan™ 200 and LABScan3D™ instruments
The LABScreen COVID Plus assay is specifically designed to truly distinguish and characterize the humoral response to COVID-19 infection. With this product, transplant centers can know with confidence if a patient has been infected, even in asymptomatic cases, by identifying the specific COVID-19 antibody present and can then decide to manage the patient accordingly.
In this unprecedented time, we must adapt in order to meet the changing and unique needs of transplant patients. The LABScreen COVID Plus solution will help us rise to this challenge.
The LABScreen COVID Plus assay is for professional, in vitro diagnostic use only.
- This test has not been FDA cleared or approved.
- Use of this product is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform moderate or high complexity tests.
- This test has been authorized only for the presence of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens.
- Boyarsky BJ, Po-Yu Chiang T, Werbel WA, et al. (2020) Early impact of COVID-19 on transplant center practices and policies in the United States. Am J Transplant. 20(7):1809-1818. doi:10.1111/ajt.15915.
- Cravedi, P, Mothi, SS, Azzi, Y, et al; for the TANGO study group. COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium. Am J Transplant. 2020; 00: 1– 9. https://doi.org/10.1111/ajt.16185.
- D’Orsogna L, van den Heuvel H, van Kooten C, Heidt S, Claas FHJ. (2017) Infectious pathogens may trigger specific allo-HLA reactivity via multiple mechanisms. Immunogenetics. 69(8-9):631-641. doi:10.1007/s00251-017-0989-3.
- Locke JE, Zachary AA, Warren DS, et al. (2009) Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant. 9(9):2136-2139. doi:10.1111/j.1600-6143.2009.02764.
- Katerinis I, Hadaya K, Duquesnoy R, et al., (2011) De novo antiHLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant 11:1727– 1733.
- Karahan GE, Claas FH, Heidt S (2015) Detecting the humoral alloimmune response: we need more than serum antibody screening. Transplantation 99:908–915.
- Huang T, et al. (2020) A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease. medRxiv 2020.04.14.20065771.
- Atyeo C, Fischinger S, Zohar T, et al. Distinct Early Serological Signatures Track with SARS-CoV-2 Survival [published online ahead of print, 2020 Jul 30]. Immunity. 2020;doi:10.1016/j.immuni.2020.07.020.
- Chi X, Yan R, Zhang J, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 [published online ahead of print, 2020 Jun 22]. Science. 2020;eabc6952. doi:10.1126/science.abc6952.